Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. - Wikidata - awgldk - TriplyDB

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.

http://www.wikidata.org/entity/Q34029815

about

Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome Ocular features in Alport syndrome: pathogenesis and clinical significance Three-dimensional electron microscopy reveals the evolution of glomerular barrier injury.Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury.The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia.Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.The glomerular basement membrane as a barrier to albumin.Searching for a treatment for Alport syndrome using mouse models Improving mutation screening in familial hematuric nephropathies through next generation sequencing.Identification of microRNAs and their target genes in Alport syndrome using deep sequencing of iPSCs samples.Multiple kidney cysts in thin basement membrane disease with proteinuria and kidney function impairment.Progression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate Treatment Efficient Targeted Next Generation Sequencing-Based Workflow for Differential Diagnosis of Alport-Related Disorders Coinheritance of COL4A5 and MYO1E mutations accentuate the severity of kidney disease.Podocyte Depletion in Thin GBM and Alport Syndrome.Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients.Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria.A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy.Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative.Challenge in pathologic diagnosis of Alport syndrome: evidence from correction of previous misdiagnosis.Phenotypic heterogeneity in females with X-linked Alport syndrome.Albumin contributes to kidney disease progression in Alport syndrome.α1β1 integrin/Rac1-dependent mesangial invasion of glomerular capillaries in Alport syndrome.Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases.The variable course of women with X-linked Alport Syndrome.A Novel Mutation in a Japanese Family with X-linked Alport Syndrome.Alport syndrome: a rare cause of uraemia.Alport syndrome: facts and opinions.Feasibility of repairing glomerular basement membrane defects in Alport syndrome.An update on the pathomechanisms and future therapies of Alport syndrome.Educational paper: Progression in chronic kidney disease and prevention strategies.Alport syndrome--insights from basic and clinical research.How benign is hematuria? Using genetics to predict prognosis.Cell-matrix adhesion of podocytes in physiology and disease.Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.The collagenopathies: review of clinical phenotypes and molecular correlations.Treatment strategies to prevent renal damage in hypertensive children.New therapeutic strategies under development to halt the progression of renal failure.Familial haematuria: when to consider genetic testing.Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment.

P2860

Q26748817-9A462989-EF93-4168-9BA8-8134D97AB838 Q28080691-1E2B9EF4-E1AB-49DF-9BCA-42523155DCB3 Q30820232-69B1144D-A454-4A6F-BF0D-BE502C80488D Q33765990-AA26A4B3-E13D-437A-9F3C-6BF85FF885BB Q33858105-27E2C6C2-EC4E-497A-8DF2-654C28507F14 Q34301017-85875B01-B634-487E-8937-5EE83583AF2F Q34351478-DBFA7226-B6EB-4772-BE1E-62E976396779 Q34453272-D2E71524-5748-4401-901A-FAC779BA125E Q34568742-CD393129-8315-47A7-B465-FB38FD1AC20D Q35170636-F9AD9071-75B9-4B06-AF1F-9A26B4A2B7CB Q35227568-A978C799-16AD-42DC-8E76-A85389AE0C41 Q35837373-965DF643-5CDA-4B23-8C60-23E253CFF44D Q35942967-BE13D6FF-6821-4678-9ECF-522BBB844E70 Q35952630-1DCE9B9D-01DF-4721-9AAF-ED9E66649734 Q36021415-6DD12C87-2FAA-4C9B-B66E-17A547E1C238 Q36090578-6D17C448-9CB6-42E1-9081-0D95C8F0F770 Q36106884-60891858-19E6-42A2-AC95-9227297A9355 Q36306757-58F76454-A72E-4B71-B8ED-429FBF885663 Q36420940-1691C0E1-4A89-4232-A216-ECF8AC10399F Q36556406-552A97AF-ABE7-485A-B053-A27C31EFD8D1 Q37054199-30031CEF-986A-46E7-A588-4397156E216D Q37139486-D57BAE36-9F80-4CB6-8787-481D085568C1 Q37218239-CA8E3C52-9CCE-4AE8-ACB1-E221D8E144BC Q37340215-77CE89C9-65B3-4E07-A4BD-2E3239020679 Q37346911-D0C6A678-AA74-4C1B-B09E-E908D53203EB Q37383185-9A793E74-7634-4490-988D-7DACF72966FE Q37588428-EF900897-4146-4D94-B13B-F5D2A4AF4DBC Q37595448-8BE74D4C-1FBC-48C1-93D5-35B578012A5C Q37670342-F4B1B00F-CC2C-4AF8-8E59-C2B7D8A9EFEA Q38035773-04EB8EFE-3600-4891-81CC-DE1A94619B81 Q38042582-755D04D0-35F3-4BBD-BA01-D8A62D225E7F Q38061008-548B85D9-F039-4908-8C20-4ABE572DCF65 Q38074565-BD33E440-DCB0-48EF-8479-4E014E3B8459 Q38075788-8A1B4D4D-709E-4889-8705-994AAA02B669 Q38087529-CE55A717-F751-454F-BE9C-7F2B1D6E68E5 Q38171408-A016FB0B-4009-46FD-9A79-66BA5C5AF6CC Q38187597-01845064-2D5A-403B-8282-3FEB95866C71 Q38201504-F672AA39-B55E-4324-B9E4-E5ED873B7940 Q38204264-65B93ABA-28B4-46F1-8A09-D3B51CFD35FE Q38238367-91C58294-30A6-4D0B-8D0E-7B237F0D83D0

P2860

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.

http://www.wikidata.org/entity/Q34029815

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Early angiotensin-converting e ...... and improves life expectancy.

@ast

Early angiotensin-converting e ...... and improves life expectancy.

@en

Early angiotensin-converting e ...... and improves life expectancy.

@nl

type

label

Early angiotensin-converting e ...... and improves life expectancy.

@ast

Early angiotensin-converting e ...... and improves life expectancy.

@en

Early angiotensin-converting e ...... and improves life expectancy.

@nl

prefLabel

Early angiotensin-converting e ...... and improves life expectancy.

@ast

Early angiotensin-converting e ...... and improves life expectancy.

@en

Early angiotensin-converting e ...... and improves life expectancy.

@nl

P1433

Q34029815-FD0D4633-612F-4741-876C-F275B2BB2DBB

P1476

Q34029815-027EDCEC-6423-421C-81BF-81FD603BA5A6

P2093

Q34029815-05D0CEF9-0AC4-48F7-95C8-35C462ED1801

Q34029815-0EB00AD1-6DD7-4D19-80FB-B2BAFC0F9D92

Q34029815-11AD141B-67F3-46B6-8B06-69F4E4F7E019

Q34029815-293202A2-0B7D-4BD8-B11C-3F9D03D26434

Q34029815-2C7E4D97-7082-4D1D-830F-50DB0F98E501

Q34029815-3809AEEF-BEDD-47BB-A434-FD8BE40AF07D

Q34029815-4B8CA591-ECE5-47D8-9D08-10460915EE65

Q34029815-576A8E08-276E-41E3-A0CD-978BA3DE24C6

Q34029815-59B13026-7357-43A6-B3A9-BB58362A13FB

Q34029815-71329909-192A-4D81-B03D-B646A09CD46E

P2888

Q34029815-4C9A3F01-D981-448C-BAF4-7B54F179CBF5

P304

Q34029815-1CF75714-EA79-4852-A7C1-E44D1DADA872

P31

Q34029815-EF39692C-E81D-487B-B2E5-61E10F0FFF30

P356

Q34029815-D85EDCE4-BD70-487C-ADA1-3C59AFF726CC

P407

Q34029815-5A809713-9581-416B-88E1-4736D929F3C6

P433

Q34029815-8C056007-2FE2-42D3-BC5F-36537FCB30FD

P478

Q34029815-9E2AEB51-F507-4F55-89C2-4B2371AB63A5

P577

Q34029815-08E497C1-9E30-45AE-9DD4-648EA2926AF4

P5875

Q34029815-D4B4938E-EBA7-4BC3-95C3-288C54DD2D2D

P6179

Q34029815-CBEE1095-14F2-4447-BC3D-313C5BCAC0EA

P698

Q34029815-53188D27-C640-4272-B2D8-F8B82B66023F

P921

Q34029815-0D8644F3-8D78-46F4-A004-4993CDF68408

P356

P1433

Kidney International

P1476

Early angiotensin-converting e ...... and improves life expectancy.

@en

P2093

Bernd Hoppe

http://www.w3.org/2001/XMLSchema#string

Bertrand Knebelmann

http://www.w3.org/2001/XMLSchema#string

Bodo Beck

http://www.w3.org/2001/XMLSchema#string

Britta Höcker

http://www.w3.org/2001/XMLSchema#string

Burkhard Tönshoff

http://www.w3.org/2001/XMLSchema#string

Christoph Licht

http://www.w3.org/2001/XMLSchema#string

Dirk E Müller-Wiefel

http://www.w3.org/2001/XMLSchema#string

Gerhard A Müller

http://www.w3.org/2001/XMLSchema#string

Hans J Anders

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Grunfeld

http://www.w3.org/2001/XMLSchema#string

P2888

P304

494-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2011.407

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51876007

http://www.w3.org/2001/XMLSchema#string

P6179

1052369873

http://www.w3.org/2001/XMLSchema#string

P698

22166847

http://www.w3.org/2001/XMLSchema#string

P921

life expectancy